Kyoto University
Graduate School of Medicine
Medical Innovation Center

• 

  TK (Takeda-Kyoto University) Project

  A five-year R&D project for new drugs to treat obesity and schizophrenia led by Professors Kazuwa Nakao, Kenji Kangawa and Akira Sawa.
  (FY2011～FY2015)

• 

  DSK (Dainippon Sumitomo-Kyoto University) Project

  A ten-year R&D project for new drugs to treat cancer led by Professors Makoto Noda, Nagahiro Minato, Kazuhiro Iwai. (FY2011～FY2020)

• 

  TMK (Mitsubishi Tanabe-Kyoto University) Project

  The “Basic and Clinical Research Project Towards Innovative Therapies for Chronic Kidney Disease”, a joint project (led by Professor Motoko Yanagita) with Mitsubishi Tanabe Pharma Corporation, was implemented from March 2011 (the start of Period 1) to June 2021 (the end of Period 2) to overcome chronic kidney disease and its complications, and was taken over to Mitsubishi Tanabe Pharma Corporation's internal project.

• 

  SK (Shionogi-Kyoto University) Project

  The SK project in collaboration with Shionogi & Co., Ltd. aimed to create innovative new drugs for Alzheimer's disease and other central nervous system diseases in the first phase (FY 2013 to FY 2017). In the second phase of the SK project (FY 2018 to 2022), we aimed to create groundbreaking new drugs by elucidating the relationship between disorders of neuronal networks and the symptoms observed in various psychiatric disorders that cause "difficulty in life". The research results of the 1st and 2nd stages have been carried over to an internal project of Shionogi & Co., Ltd.

• 

  Alliance Laboratory for Advanced Medical Research (Alliance Station)

  Alliance Station (A-Station), led by Professor Narumiya, is an advanced open innovation model built on our experiences of the AK project.
  A-Station aims to create innovative drugs through joint research projects with various research groups and clinical departments in Kyoto University.
  

• 

  Department of Immunosenescence

  A four-year R&D collaboration with Ono Pharmaceutical Co., Ltd. for new drugs to treat age-related diseases led by Professor Masakazu Hattori.
  (FY2018～FY2021)
  

• 

  Department of Regulation of Neurocognitive Disorders

  Department of Regulation of Neurocognitive Disorders is an alliance between Cyn-K, LLC (USA) and Department of Neurology of Kyoto University Graduate School of Medicine. In our department, we will use the platform technology discovered and developed by VLP Therapeutics (USA), co-founded by our industry collaborator, and investigate the effects of the vaccine targeting a pathogenesis protein associated with neurocognitive disorders on such disorders, as well as elucidate the mechanism of brain degeneration and aging. We aim to develop three types of vaccines according to the progression of the disease.
  

• 

  Laboratory of Tumor Tissue Response

  R&D joint collaboration with Sumitomo Pharma Co., Ltd., led by Professor HAGIWARA, aims at new drug discovery by analyzing the intercellular response including immune cells and stroma in tumor microenvironment. In addition, based on the industry-academia collaboration system cultivated through the DSK project, etc., we aim to quickly create original and epoch-making therapeutic drugs by advanced technologies such as drug discovery using iPS cells, not limited to the oncology area.
  

• 

  Department of Personalized Cancer Medicine

  SCREEN Holdings Co., Ltd., AFI Corporation and KyoDiagnostics K.K. have established a dedicated laboratory within Kyoto University’s Medical Innovation Center. The facility will enable the partners to perform joint research leading to the development of new personalized cancer therapies that use the patient’s own cells to accurately predict the effects of different treatments in vitro. The partners will work together to stage a series of demonstration experiments, with the goal of delivering a system able to predict the therapeutic effects of different cancer treatments.
  

• 

  Department of Adaptive and Maladaptive Responses in Health and Disease

  Department of Adaptive and Maladaptive Responses in Health and Disease is a collaboration project with Meiji Holdings Co., Ltd., led by Professor Motoko Yanagita. We aim to reveal the underlying mechanisms of microbiome-mediated health and diseases and tissue aging to overcome such diseases.
  

Sister Project

• 

  Center for Innovation in Immunoregulative Technology and Therapeutics
  (AK Project)

  AK project, led by Professor Narumiya, was an organizational alliance between Kyoto University and Astellas Pharmaceutical Inc., which was carried out in Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program of Ministry of Education, Culture, Sports, Science and Technology. AK project aimed at creation of innovative immunoregulative medicines through a new drug discovery model in post genome era, and nurture of drug discovery researchers.
  (FY2007～FY2017)
  
  Reference